Emavusertib

N/A

Report date: 2026/05/23 20:00:57

Base Information

Drug NameEmavusertib
Drug Alias NameAU-4948CA-4948
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionTyrosine-protein kinase receptor FLT3 inhibitorsInterleukin-1 receptor-associated kinase 4 inhibitors
TargetsTyrosine-protein kinase receptor FLT3Interleukin-1 receptor-associated kinase 4
Therapy Area/IndicationsGastroesophageal Junction NeoplasmsMyelodysplastic SyndromesAnemia +[18] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCzechiaUnited StatesPoland +[8] 
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesAurigene
China Registration ClassN/A

Develop Information

Active CompaniesWashington University School Of MedicineNational Cancer InstituteCuris Inc
Inactive CompaniesLeipzig UniversityUniversity Of Florida
Active IndicationsGastroesophageal Junction NeoplasmsUrologic NeoplasmsStomach Neoplasms +[12] 
Inactive IndicationsMyelodysplastic SyndromesAnemiaPancreatic Neoplasms +[6] 

Other Information

ATC CodeN/A
Related LinksN/A